Premium
Matrix metalloproteinase 9 expression and survival of patients with osteosarcoma: a meta‐analysis
Author(s) -
Liu Y.,
Wang Y.,
Teng Z.,
Chen J.,
Li Y.,
Chen Z.,
Li Z.,
Zhang Z.
Publication year - 2017
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/ecc.12364
Subject(s) - medicine , osteosarcoma , confidence interval , meta analysis , oncology , population , biomarker , pathology , genetics , environmental health , biology
Several studies have evaluated the effect of matrix metalloproteinase‐9 ( MMP ‐9) expression on the overall survival of patients with osteosarcoma, but the results remain conflicting. To examine the prognostic significance of MMP ‐9 expression in osteosarcoma risk, we conducted this meta‐analysis to systematically review the published studies. We searched the commonly used electronic databases updated to September 2013 for relevant studies which evaluated the correction between MMP ‐9 expression and survival of patients with osteosarcoma. Overall, a total of eight studies including 437 cases were screened out. No significant heterogeneity was observed between studies. The MMP ‐9 was expressed in 73.9% (323/437) of cases, and the results showed that MMP ‐9 expression was associated with increased mortality rate of osteosarcoma during the follow‐up (risk ratio = 2.79, 95% confidence interval, CI = 1.96–3.97, P < 0.00001). By ethnicity analysis, a significant correction was also found between MMP ‐9 expression and osteosarcoma risk among Asian and non‐Asian population ( P < 0.001), indicating that MMP ‐9 was an indicator of prognosis of osteosarcoma. In conclusion, this meta‐analysis indicated that MMP ‐9 expression might be a biomarker of poor prognosis for patients with osteosarcoma. However, the prognostic value of MMP ‐9 on survival of osteosarcoma patients still needs further large‐scale trials to be clarified.